{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigu7zedhimgznkhgrxpxm22shzjqqfiy5klzhqpu5yld2kcrnjwoy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3moisygkqsog2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreig4uosmebk3txmvmaqdelbevji6qdtvxrpfgg6dwlwbphzaqgyg7y"
    },
    "mimeType": "image/jpeg",
    "size": 725707
  },
  "path": "/news/2026-06-therapeutic-thrombi.html",
  "publishedAt": "2026-06-17T12:40:08.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Antiplatelet drugs are one of the main tools used to prevent thrombus formation in people who have had a heart attack or stroke or who have cardiovascular diseases with a high thrombotic risk. These treatments work by reducing platelets' ability to aggregate and form clots that can obstruct the arteries. However, their use also increases the risk of bleeding, a common complication that limits their use in certain patients and remains one of the major challenges in cardiology today.",
  "title": "Researchers discover a new therapeutic target to prevent thrombi with a lower bleeding risk"
}